SEC Filing Summary: Athira Pharma, Inc. (ATHA)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. on May 9, 2025. The filing serves as a current report to announce the issuance of a press release detailing financial results for the quarter ended March 31, 2025. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in Bothell, WA.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the body of this 8-K document.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this filing. The document solely notifies investors of the availability of the Q1 2025 results via the attached press release.
Guidance, Outlook, and Risks
- Disclosure Channels: The Company utilizes its website, investor relations portal, and social media accounts (X, LinkedIn, Instagram, Facebook) to disseminate material information.
- Regulation FD: Item 7.01 confirms that the press release and associated communications constitute material information under Regulation FD.
- Legal Status: The information in Items 2.02 and 7.01 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release dated May 9, 2025) for actual financial figures and operational updates.
- Verify the Company's status as an Emerging Growth Company and any associated accounting transition periods.
- Check the Company's official investor relations website and social media channels for additional context on the Q1 2025 results.
- Confirm the trading symbol ATHA on The Nasdaq Capital Market.